Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients-Reference-Cited by-同舟云学术

Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients

Published:2010-04 Issue:4 Volume:21 Page:815-819
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Laé M.,Couturier J.,Oudard S.,Radvanyi F.,Beuzeboc P.,Vieillefond A.

Funder

Institut National du Cancer. Funding to pay the Open Access publication charges for this article was provided by Institut Curie

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/21/4/815/366736/mdp488.pdf

Reference30 articles.

1. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer;von der Maase;J Clin Oncol,2005

2. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007;Goldhirsch;Ann Oncol,2007

3. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

4. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial;Smith;Lancet,2007

5. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;Romond;N Engl J Med,2005

Cited by 165 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disitamab vedotin (RC48) long-term regimen in a post-nephroureterectomy patient with metastases: a case report;Frontiers in Oncology;2024-09-13

2. Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer;Targeted Oncology;2024-04-03

3. Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma;Frontiers in Pharmacology;2024-03-20

4. Effects of trastuzumab emtansine on canine urothelial carcinoma cells in vitro and in vivo;Veterinary and Comparative Oncology;2024-03-19

5. HER2-targeted therapies in cancer: a systematic review;Biomarker Research;2024-02-02